Abstract
Walnut has been reported to have beneficial effects on improving cognitive performance. This randomized double-blind placebo-controlled clinical trial evaluates the clinical effectiveness and safety of walnut oligopeptide (WO) on memory enhancement, cognition, and sleep quality in teenagers and elderly people. Eighteen teenagers and 18 elderly people were, respectively, randomly allocated to placebo, low dosage (170 mg), and high dosage (340 mg) WO administration groups (n = 6 per group in each population). After 90 days of administration, the Wechsler Adult Intelligence Scale (WAIS) score was significantly increased and the global Pittsburgh Sleep Quality Index (PSQI) score was significantly decreased in the WO administration group. In addition, the average scores for test subjects of Chinese, Mathematics, and English examinations were significantly increased from the baseline for the teenagers in the WO administration group. Our results support the claim that WO has the potential to become a new option for nutritional intervention, to enhance the memory, cognitive ability, and sleep quality of teenagers and elderly people. This study was approved by the Institutional Review Board of the Shanghai Nutrition Society and registered at the Chinese Clinical Trial Registry ( http://www.chictr.org.cn ) with an ID number of ChiCTR1900028160.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
